#fda

3 articles tagged #fda.

#2026 3 #503a 1 #503b 2 #FDA 1 #alternatives 1 #ban 1 #before-and-after 1 #beginners 2 #brand-name 3 #bridge-program 2 #comparison 2 #compounded 7 #compounded-semaglutide 1 #compounded-tirzepatide 1 #compounding-ban 1 #copay 1 #cost 12 #countdown 1 #coupon 1 #coverage 1 #diabetes 1 #diet 1 #dosage 1 #eli-lilly 3 #enforcement 1 #enrollment 1 #fact-check 1 #fda 3 #fda-approval 1 #flat-rate 1 #foundayo 6 #framework 1 #glp-1-patches 1 #glucose-monitors 1 #guide 1 #hhs 1 #hims 1 #how-to-get 1 #injectable 5 #injection 1 #insurance 11 #ivy-rx 1 #ivyrx 1 #legality 1 #liraglutide 1 #medicaid 1 #medicare 6 #mounjaro 5 #news 3 #novo-nordisk 1 #oral-glp1 6 #oral-semaglutide 1 #orforglipron 4 #ozempic 5 #pill 1 #policy 1 #prior-authorization 1 #regulation 2 #results 1 #rfk 1 #ro 1 #safety 3 #savings-card 1 #schedule 1 #semaglutide 16 #shortage 1 #side-effects 9 #supplements 1 #surmount 2 #telehealth-review 1 #timeline 1 #tirzepatide 17 #wegovy 15 #wegovy-pill 3 #weight-loss 24 #without-insurance 1 #zepbound 17

Editorial lifestyle photograph of official documents on an oak desk illustrating a regulatory proposal

News News & PipelineMay 8, 2026• 7 min read

FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list — forever, not just during shortage enforcement. Public comment closes June 29, 2026. If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.

Editorial lifestyle still-life accompanying a guide to Zepbound side effects and management

Guide Side Effects & SafetyApril 20, 2026• 10 min read

Zepbound Side Effects (2026): Nausea 29%, Diarrhea 23%, Vomiting 13% — Full Guide with SURMOUNT Trial Data

Verified April 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials — nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

Editorial photograph illustrating FDA GLP-1 warning letters and enforcement actions

News News & PipelineApril 11, 2026• 7 min read

FDA Issues 14 New GLP-1 Compounder Warning Letters (March-April 2026 Enforcement)

Verified April 11, 2026: The FDA issued 14 new warning letters to GLP-1 compounders between March 12 and April 8, 2026 — the largest enforcement wave since the semaglutide compounding ban. Full list of affected pharmacies, what they violated, and what to do if you were a patient.

#fda

FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Zepbound Side Effects (2026): Nausea 29%, Diarrhea 23%, Vomiting 13% — Full Guide with SURMOUNT Trial Data

FDA Issues 14 New GLP-1 Compounder Warning Letters (March-April 2026 Enforcement)

Embody

Gala

Sesame Care